Estetrol: The Definitive Guide

What is estetrol?

Estetrol, or E4, is an estrogen molecule that is naturally produced by the fetal liver during pregnancy and manufactured for medicine. It is the estrogen in two very different kinds of product: an estrogen-only menopausal tablet and an estrogen-plus-progestin contraceptive. The product name, country and indication are essential to interpreting its dose and evidence. [1], [3]

Fylrevy received EU marketing authorization on March 26, 2026 for estrogen-deficiency symptoms in postmenopausal women after hysterectomy, and in those with a uterus who have had no period for at least 12 months. It is no longer merely an investigational menopause medicine in the EU. A January committee recommendation was an earlier step, not the final authorization. [2], [9]

The verified US product is Nextstellis, which combines estetrol with drospirenone to prevent pregnancy. No FDA menopause authorization for Fylrevy was located in the current checks; the US sources retrieved describe contraception. EU approval does not authorize a US menopause prescription or establish local stock in any country. This guide therefore keeps the verified European regimen separate from US contraceptive information. [2], [3], [5]

Typical Estetrol Protocols

Fylrevy’s estrogen-only tablet does not contain the progestogen needed with an intact uterus. Its label specifically requires adding an approved progestogen continuously. This is not a default instruction for cyclic progesterone borrowed from an estradiol guide. With a uterus, the starting strength is 14.2 mg and an increase to 18.9 mg is considered when symptom relief is insufficient. After hysterectomy, the labeled dose is 18.9 mg; progestogen is generally not added unless a prior endometriosis diagnosis changes the decision. [1]

Take one Fylrevy tablet at approximately the same time each day, with or without food. If a tablet is missed, take it as soon as possible, but when more than 12 hours have elapsed, skip it and continue with the next tablet. Do not use the Nextstellis missed-pill rules for Fylrevy: a contraceptive combination has different consequences and instructions. [1], [3]

The label strengths describe estetrol as estetrol monohydrate. Older trial descriptions may use different presentations of the hormone’s mass. Copy the named commercial tablet strength from its label instead of creating a replacement prescription from a research summary. There is no verified milligram conversion from Fylrevy to an estradiol patch or CEE tablet. [1]

Evidence note: the menopause rows are complete population-specific EU SmPC schedules. The US row is a labeled contraceptive comparison, not a menopausal regimen or a recommendation to use a birth-control pill for menopause.

What benefits are established for menopause?

Fylrevy is authorized for postmenopausal estrogen-deficiency symptoms, including vasomotor symptoms such as hot flashes. Its development program measured reductions in the frequency and severity of moderate-to-severe hot flashes. This is a symptom-treatment indication; it is not an authorization for contraception, preventing dementia, cardiovascular prevention or a general anti-aging program. [1], [2]

The indication with a uterus requires the stated time since the last period. It should not be silently extended to everyone with irregular perimenopausal cycles or to POI replacement. Other estrogen products and clinical circumstances have their own guidance, but those cannot enlarge Fylrevy’s exact label population. Persistent vaginal symptoms may need their own local assessment and treatment rather than assuming a systemic tablet solves every aspect of GSM. [1], [6]

A good treatment goal is concrete: fewer disruptive hot flashes, fewer sweat-related awakenings or a measurable improvement in daily functioning. “Balance my hormones” is too vague to judge response and can encourage unnecessary changes. Decide beforehand which symptoms are being treated and what adverse effects would change the plan. [1], [6]

What did the menopause trials find?

The EU SmPC describes two phase 3 studies with a randomized double-blind placebo-controlled efficacy part and a longer open-label safety part. The key symptom assessments were at four and 12 weeks. Both 14.2 mg and 18.9 mg reduced hot-flash frequency compared with placebo at those points. The 18.9 mg dose also reduced severity at both points; the lower dose met the severity comparisons in one study but not the other. That distinction is more useful than calling every outcome uniformly positive. [1]

Evidence for symptom benefit does not establish long-term comparative safety. The trials were not head-to-head demonstrations that Fylrevy prevents more clots or breast cancers than an estradiol patch, CEE or another estrogen. Measurements of clotting proteins and metabolism are biomarkers, not the same outcomes as a confirmed clot or cancer. A promising pharmacologic profile can be a research rationale without being a clinical safety advantage. [1], [4]

Uterine and bleeding findings are particularly relevant. In the pivotal population with a uterus and at least 12 months since menses, treated with estetrol 18.9 mg plus continuous progesterone 100 mg, the label’s warnings report vaginal bleeding in 66.8% and disordered proliferative endometrium in 5.4%. These are different outcomes, not percentages of endometrial cancer. These findings matter when assessing the lower labeled start with a uterus and the requirement for appropriate continuous progestogen. The label notes that higher progesterone doses or other approved progestogens may be used, while safety and tolerability data for those combinations are unavailable. [1]

Does its mechanism make it safer?

Estetrol binds estrogen receptors and replaces estrogen signaling lost after menopause. It has pharmacologic differences from estradiol and ethinyl estradiol, including a different pattern of metabolism. The EU label describes predominantly glucuronidation and sulfation, with CYP450 enzymes not playing a major metabolic role. That does not mean the medicine has no drug interactions, no liver precautions or no systemic effects. [1]

The FDA’s 2025 letter about Nextstellis promotion is a useful example of the boundary between mechanism and outcomes. It objected to promotional presentations suggesting that “low-impact” properties made the contraceptive intrinsically safer than other estrogen-containing contraceptives. This letter concerns that combined contraceptive, not an FDA evaluation of Fylrevy. Its broader lesson is to demand clinical comparative evidence before turning a laboratory result into a safety promise. [4]

Descriptions such as “selective,” “native estrogen” or “plant-derived” should therefore stay separate from prescribing eligibility. A manufactured hormone can match a naturally occurring molecule and still stimulate the uterine lining, produce bleeding and have contraindications. [1]

What risks and eligibility limits matter?

Fylrevy’s contraindications include known or suspected estrogen-sensitive cancer, unexplained genital bleeding, untreated endometrial hyperplasia, previous or current venous thromboembolism, inherited clotting disorders, active or recent arterial thromboembolic disease and significant liver disease. Breast pain and tenderness and uterine/bleeding findings appear in its safety information. Additional monitoring means suspected adverse effects should be reported; it does not mean the medicine is only experimental. [1], [2]

The label does not recommend Fylrevy in moderate or severe renal impairment and has no dose recommendation for people starting after age 65 because safety and efficacy were not studied in that population. A general menopause timing guideline cannot fill in that missing product evidence. Review medicines, liver and kidney history and the complete progestogen plan before starting. [1], [7]

Seek urgent assessment for symptoms suggesting a clot or stroke, including sudden breathlessness, chest pain, a painful swollen leg, sudden weakness, speech difficulty or loss of vision. Jaundice, a new migraine-type headache or a significant blood-pressure rise requires prompt clinical advice and can require stopping under the label. Tell the surgical team about treatment before an operation. [1]

Nextstellis has its own contraceptive contraindications and monitoring, including drospirenone-related potassium concerns. Its existing progestin is not evidence that every estetrol menopause regimen has adequate protection, and its adverse-effect reports cannot isolate the estrogen ingredient. [3]

What should you record and review?

The Fylrevy label requires a careful benefit-risk appraisal at least annually. General menopause guidance also recommends an early review after treatment starts, sooner for difficulties. Record the exact tablet strength, progestogen product and continuous schedule, missed tablets, hot-flash changes, sleep, bleeding and adverse effects. Symptom relief and uterine tolerability are separate outcomes. [1], [6]

Bleeding is common in the studied uterine regimen, but that does not make persistent bleeding safe to ignore. Assess its pattern and clinical context; a label incidence is not a rule for waiting. NICE recommends prompt assessment when unscheduled bleeding persists beyond six months after starting systemic HRT or three months after a change, and concerning bleeding can require earlier assessment. [1], [6]

There is no universal blood-estetrol target presented in the approved regimen. Tests should answer specific questions from history, symptoms or concomitant medicines rather than a routine panel invented for a new estrogen. Appropriate breast and other screening follows clinical needs. Check that a suggested monitoring requirement belongs to Fylrevy rather than to a drospirenone contraceptive. [1], [3], [6]

Can you stop or change estetrol treatment?

Discuss the reason for changing treatment, the symptoms likely to recur and the replacement plan. The Fylrevy leaflet says you can stop, but should speak with the doctor first. General guidance allows gradual reduction or immediate cessation of menopausal HRT; it does not supply a validated home-made Fylrevy taper. Do not split or substitute strengths without product-specific advice. [1], [6]

If systemic estrogen is continuing during a change, do not remove required progestogen protection independently. A switch from cyclic or sequential HRT has a starting instruction in the Fylrevy label: begin the day after completion of the previous regimen. Contraceptive discontinuation is a separate problem if pregnancy prevention is still needed. A suspected serious reaction requires urgent assessment rather than a routine switch. [1], [3]

How should Fylrevy be stored?

The EU product information states that Fylrevy requires no special storage conditions. Keep it in its supplied package, out of children’s reach, and observe the expiry. “No special conditions” is not permission to ignore extreme heat, damage or expiry; ask a pharmacist if the package has been compromised. Unused medicine should be disposed of under local requirements. [1]

The Nextstellis package has its own storage information. Do not substitute a contraceptive leaflet for Fylrevy or assume that an imported blister has the correct authorization, content and local instructions merely because the ingredient name matches. [1], [3]

How does it compare with other estrogen options?

Fylrevy provides a new oral menopausal option where authorized. Estradiol tablets, skin patches and gels and oral CEE are different established formulations, each with product-specific schedules. A new approval can broaden choice without demonstrating superiority in every outcome. Ease of use, symptom relief, bleeding, adverse effects, local access and a feasible protection regimen all matter. [1], [6], [7]

Nextstellis, Drovelis and other estetrol contraceptive brands are combinations with separate populations and regulatory records. Their use cannot stand in for evidence about estrogen-only Fylrevy with an added progestogen. A preference for estetrol’s mechanism should not obscure the need to check the exact indication and long-term uncertainty. Authorization across the EU also does not mean a tablet is already reimbursed or stocked in every member state. [1], [2], [3]

What can public contraceptive reviews tell us?

The retrieved Nextstellis review page includes accounts of improved cycle-related symptoms and mood, alongside low mood, reduced libido, spotting, breast symptoms and discontinuation. Some writers discuss perimenopause, but the medicine remains the estetrol-drospirenone contraceptive combination. These reports cannot isolate estetrol’s effects or establish the response rate to Fylrevy. [8]

We use qualitative themes without names, quotes, ratings or vote counts. No freshly verified Fylrevy menopause community dataset was found in this bounded check. The useful questions are whether the clinician is treating contraception, cycle symptoms or postmenopausal hot flashes, and which product and evidence match that goal. A favorable contraceptive review is not long-term comparative safety evidence for menopausal use. [1], [3], [8]

Common questions about estetrol

Is estetrol still investigational for menopause?

Not everywhere. Fylrevy received final EU authorization in March 2026. No FDA menopausal authorization was located in the checked US records; Nextstellis is approved contraception. [2], [3], [5] A positive regulatory opinion and final authorization are different events, and menopause treatment and contraception remain different indications. The EU product information now defines Fylrevy’s population and schedule, while the US contraceptive record does not establish a menopause license. Local marketing, reimbursement and stock still require checking. See authorization and product scope. [1], [2], [3], [5]

Does Fylrevy contain progesterone?

No. It is estrogen-only. With a uterus, its label requires an approved progestogen added continuously. [1] Its endometrial evidence belongs to the specified complete regimen, including that continuous progestogen requirement. Do not assume an estrogen-only tablet protects the lining or use a contraceptive component as an automatically equivalent replacement. The actual progestogen and complete schedule need prescribing review. See the named protocol. [1]

Is the starting dose the same after hysterectomy?

No. With a uterus the start is 14.2 mg, while after hysterectomy the labeled dose is 18.9 mg. Follow the exact population row. [1] Uterus status is an explicit population distinction in this label, not a reason to calculate your own increase or use another product’s dose. The accompanying treatment and eligibility also matter. If symptoms remain troublesome, ask about label-described adjustment and review of the complete plan. See the population-specific rows. [1]

Is a lower clot risk proven?

The checked menopause label does not establish comparative superiority to other estrogen regimens. Biomarker differences and contraceptive promotional claims cannot prove fewer clinical clots. [1], [4] The relevant outcome is clinical events in the treated population, not simply how a marker changes in a laboratory study. A distinct mechanism can generate useful research questions without guaranteeing fewer clots or cancers. Individual contraindications and systemic precautions still apply. See mechanism and its limits. [1], [4]

Does bleeding mean the regimen is failing?

Bleeding is reported frequently in the studied uterine regimen, but requires assessment according to its pattern and context. It is neither proof of inadequate dose nor permission to ignore persistent bleeding. [1], [6] Tell the clinician when bleeding began, its pattern and any treatment changes or missed components. Do not interpret bleeding alone as a serum target or an instruction to add estrogen. The product-specific regimen and current assessment pathway should guide the next step. See monitoring and review. [1], [6]

Can Nextstellis substitute for Fylrevy?

It is a different combined product, population, schedule and indication. Do not use its pill pack as an estrogen-only menopause regimen. [1], [3] A contraceptive pack contains an additional hormone and a calendar designed for its own purpose. The approved menopause product has different instructions and a separate protection requirement when the uterus is present. Ask for a named complete alternative if access is difficult. See the comparison. [1], [3]

Does EU approval mean it is stocked locally?

Authorization and commercial availability are different. Verify the local prescribing and pharmacy pathway rather than assume stock or reimbursement. [2] A regulator can authorize a medicine before every pharmacy supplies it, and a benefit program may have its own eligibility rules. Ask the clinician and pharmacy about the exact country product, prescription pathway and current availability. This guide establishes the regulatory record, not a guaranteed purchase route. See the verified scope. [2]

Glossary

Definitions for interpreting the products, evidence and limits.

Estrogen

A hormone class that includes estradiol, estrone and estriol.

Bioidentical

Having the same molecular structure as a hormone made by the body; not a safety certification.

MHT / HRT

Menopausal hormone therapy; hormone replacement therapy is a broader term.

Vasomotor symptoms

Menopausal hot flashes and night sweats.

GSM

Genitourinary syndrome of menopause: symptoms and tissue changes involving genital and urinary areas.

Systemic treatment

Medicine delivered through the circulation to act throughout the body.

Local treatment

Treatment directed mainly at the tissue where it is applied; some absorption can still occur.

First-pass metabolism

Initial liver processing after a swallowed medicine is absorbed from the gut.

Endometrium

The lining inside the uterus.

Endometrial hyperplasia

Excess growth of uterine lining; some forms can precede cancer.

Progestogen

A medicine class including progesterone and synthetic progestins, used for uterine protection in systemic HRT.

Micronized progesterone

Progesterone processed into small particles to support absorption; route and schedule remain important.

Continuous combined

Estrogen and progestogen taken without planned monthly breaks.

Sequential

Progestogen taken during a defined part of an estrogen-treatment cycle.

Withdrawal bleed

A planned bleed associated with stopping the progestogen part of a sequential regimen.

Hysterectomy

Surgery to remove the uterus; it does not always remove the ovaries.

VTE

Venous thromboembolism: a clot in a vein, including leg clots and pulmonary embolism.

Pulmonary embolism

A clot blocking an artery in the lungs; a medical emergency.

Absolute risk

How often an event occurs in a specified population over a specified time.

Relative risk

An event rate in one group compared with another; it needs baseline risk to show practical size.

Compounded product

A pharmacy-prepared medicine; approval of an ingredient does not approve the finished preparation.

Contraindication

A circumstance in which a medicine should not be used according to its label.

Estetrol / E4

An estrogen naturally produced by the fetal liver during pregnancy and manufactured for medicine.

Drospirenone

The progestin combined with estetrol in Nextstellis; it has its own effects and precautions.

SmPC / RCP

Summary of Product Characteristics: professional product information for an authorized medicine.

Biomarker

A measurable biologic indicator; it is not automatically a clinical outcome.

Phase 3 trial

A clinical trial stage evaluating benefit and safety for a proposed use.

Open-label study

A study in which participants and researchers know the treatment.

Additional monitoring

EU pharmacovigilance designation encouraging reporting of suspected adverse effects.

How was this guide researched?

Full named labels define amounts, schedules, contraindications and storage. Regulators establish authorization; clinical guidelines inform follow-up without automatically expanding a product indication. Community evidence remains separate. The directory distinguishes full access, abstract-only access and unavailable archival links.

How this page was made

This Doserly editorial guide was prepared with AI assistance using public sources checked October 2, 2026. No independent clinician reviewer is claimed. Doserly develops a commercial tracking app. Original figures explain concepts and do not represent trial results. The directory identifies source revisions and access limitations. January 2027 is a review target; new evidence can require an earlier check.

Sources and updates

Related guides